Clinical trials: Stage II Prostate Cancer
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Group Therapy Compared With Educational Materials in Patients With Prostate Cancer
RATIONALE: Developing coping strategies may help improve the quality of life of patients with prostate cancer. PURPOSE: This randomized clinical trial is comparing the effect of group therapy with written educational materials on…
- Trial name
- NCT00002848
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- 7 sites in United States
- Volunteers
- 480 people
- Sponsor
- Gary Morrow
Prostatic Diseases, Genital Neoplasms, Male
A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
The purpose of this research study is to determine the safety and effectiveness of the investigational drug, Ixabepilone, in men with high risk prostate cancer who plan to receive surgery.
- Conditions
- Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
- Trial name
- NCT00672009
- Testing
- Ixabepilone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Prostate Cancer
Selenium in Treating Patients With Prostate Cancer
RATIONALE: Selenium may prevent or slow the growth of prostate cancer. PURPOSE: This randomized phase II trial is studying how well selenium works in treating patients with prostate cancer.
- Trial name
- NCT00752739
- Testing
- selenium
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Arizona
Prostate Cancer
Prospective Evaluation of Mp-MRI, MR-guided Biopsy, and Molecular Markers for Active Surveillance of Prostate Cancer
Active Surveillance (AS) is a treatment option in patients with favorable risk prostate cancer. According to the current guidelines patients are monitored by prostate specific antigen (PSA) testing (every 3 months) and regular…
- Trial name
- PROMM-AS (NCT03979573)
- Testing
- Multiparametric MRI, Radiomics, MR-guided Biopsy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostatic Neoplasms
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
The purpose of this study is to investigate the safety, tolerability and anti-tumor effects of treatment with samarium Sm-153 lexidronam in combination with docetaxel in patients with castrate metastatic prostate cancer.
- Trial name
- NCT00121095
- Testing
- Samarium Sm-153 lexidronam + Docetaxel
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Cytogen Corporation
Prostate Cancer
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00003645
- Testing
- Flutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
The goal of this clinical research study is to learn if the addition of sunitinib malate (SU011248) to hormone based castration is an effective treatment for shrinking or controlling the tumor before having the prostate removed.
- Trial name
- NCT00329043
- Testing
- LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002633
- Testing
- bicalutamide, buserelin, flutamide
- Where
- 15 sites in Canada
- Volunteers
- 361 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Gastrointestinal Complications, Prostate Cancer
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction, Urinary Complications
- Trial name
- NCT00541047
- Testing
- bicalutamide, goserelin acetate, leuprolide acetate
- Where
- 58 sites in Canada, United Kingdom
- Volunteers
- 4,236 people
- Sponsor
- University College, London
Prostatic Neoplasm
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
One current hypothesis as to what limits duration of initial hormone response is the rapid emergence of hormone resistant prostate carcinoma cells.
- Trial name
- NCT00001266
- Testing
- Suramin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether standard radiation therapy is more effective than high-dose radiation therapy in treating patients with prostate cancer.
- Trial name
- NCT00003290
- Testing
- gonadotrophin releasing hormone, radiation therapy
- Where
- 19 sites in South Africa, United Kingdom
- Volunteers
- 800 people
- Sponsor
- Medical Research Council
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00021450
- Testing
- bicalutamide, goserelin acetate, adjuvant therapy
- Where
- 20 sites in Belgium, Cyprus and 9 more
- Volunteers
- 819 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Stage I Prostate Cancer, Stage IIA Prostate Cancer
Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer
Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer.
- Conditions
- Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00003832
- Testing
- bromodeoxyuridine, conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer
RATIONALE: Implant radiation therapy delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- J-POPS (NCT00534196)
- Testing
- Permanent iodine-125 (Brachytherapy)
- Where
- 31 sites in Japan
- Volunteers
- 6,927 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of conventional radiation therapy with high-dose radiation therapy in treating men with…
- Trial name
- NCT00002703
- Testing
- high-LET heavy ion therapy, low-LET photon therapy
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Proton Radiation Oncology Group
Prostate Cancer
Long-term Better Than Short-term ADT With Salvage RT
A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after…
- Trial name
- LOBSTER (NCT04242017)
- Testing
- Triptoreline
- Where
- 3 sites in Belgium
- Volunteers
- 394 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer
Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer
RATIONALE: New imaging procedures such as CT-on-rails™ may improve the ability to pinpoint the location of the tumor and decrease radiation therapy damage to healthy tissue.
- Trial name
- NCT00084526
- Testing
- computed tomography, ultrasound imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Calcitriol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. Dexamethasone may help calcitriol work better by making tumor cells more sensitive to the drug.
- Trial name
- NCT00524589
- Testing
- calcitriol, dexamethasone, protein expression analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
This partially randomized phase I/II trial studies the side effects and best dose of enzalutamide and mifepristone when given together and to see how well they work in treating patients with metastatic hormone resistant prostate…
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02012296
- Testing
- enzalutamide, mifepristone, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 88 people
- Sponsor
- University of Chicago